Lascco obtains US patent protecting its biomarker PSP for the diagnosis of sepsis
Lascco SA announced today that the United States Patent and Trademark Office (USPTO) issued the US Patent No. 8,435,755, related to the use of its biomarker, Pancreatic Stone Protein (PSP), for the prediction of sepsis. Earlier this year, similar patents for PSP were granted in Japan and in China.
The PSP biomarker is currently under development in partnership with global diagnostic companies for use on immunochemistry analyzers.
Sepsis, a syndrome characterized by an overwhelming systemic response to infection, is among the leading causes of death in intensive care units and accounts for 40% of their total expenditure. Every year, 18 million individuals die from sepsis. In the United States alone, the estimate of cases amounts to 1 million per year. Despite tremendous research and increasing therapeutic efforts, mortality rates from sepsis remain disappointingly high, ranging between 30% and 50%, mostly attributed to misdiagnosis or delayed diagnosis.
Lascco SA is a Swiss-based biotechnology company dedicated to the maturation of early-stage biomedical technologies. The company is based in Geneva.
Please login or sign up to comment.
Commenting guidelines